Anna Sureda Balarí

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

Vânia Hungria, Paweł Robak, Marek Hus et al. · New England Journal of Medicine · 2024 · 166 citations

Medicine, Pharmacology, Pharmacotherapy +13

GEM2017FIT Trial: Induction Therapy with Bortezomib-Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) Versus Carfilzomib, Lenalidomide and Dexamethasone (KRd) Plus/Minus Daratumumab (D), 18 Cycles, Followed By Consolidation and Maintenance Therapy with Lenalidomide and Daratumumab: Phase III, Multicenter, Randomized Trial for Elderly Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients Aged between 65 and 80 Years

María‐Victoria Mateos, Bruno Paiva, María Teresa Cedena Romero et al. · Blood · 2023 · 24 citations

Medicine, Hematology, Oncology +17

Glofitamab Plus Polatuzumab Vedotin Continues to Demonstrate Frequent and Durable Responses and Has a Manageable Safety Profile in Patients with ≥2L Relapsed/Refractory DLBCL, Including HGBCL, and in Patients with Prior CAR T-Cell Therapy: Updated Results from a Phase Ib/II Study

Martin Hutchings, Abraham Avigdor, Anna Sureda Balarí et al. · Blood · 2023 · 18 citations · Full text

Medicine, Hematology, Pharmacology +13

Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial

Vânia Hungria, Paweł Robak, Marek Hus et al. · The Lancet Oncology · 2025 · 16 citations

Medicine, Pharmacology, Pharmacotherapy +11

Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial

Vânia Hungria, Paweł Robak, Marek Hus et al. · Blood · 2024 · 14 citations

Medicine, Pharmacology, Pharmacotherapy +17